People seek ways to pause a difficult psychedelic experience. Psychedelic Science Review spotlights ketanserin’s promise. Here’s what’s known, what isn’t, and harm-reduction context for DMV readers.

Clinical trial momentum has regulators eyeing MDMA and psilocybin. Here’s how “abuse potential” factors into rescheduling talks—and what DMV readers should watch.

Psychedelic Science Review reports a rapid rise in psilocybin interest, with 100+ clinical trials since the early 2000s and recent studies signaling strong therapeutic potential.

A study reported by Psychedelic Science Review examines norpsilocin derivatives and the potential role of monoalkyl tryptamines.

Researchers finally show psilacetin (4-AcO-DMT) turns into psilocin in vivo, clarifying decades of debate and shaping future psychedelic research and policy talk in the DMV.

Psychedelic Science Review updates five years of research on gender-dependent psychedelic effects, female hormones, and 5-HT2A receptors.